JPH09502082A - 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用 - Google Patents
遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用Info
- Publication number
- JPH09502082A JPH09502082A JP6514066A JP51406694A JPH09502082A JP H09502082 A JPH09502082 A JP H09502082A JP 6514066 A JP6514066 A JP 6514066A JP 51406694 A JP51406694 A JP 51406694A JP H09502082 A JPH09502082 A JP H09502082A
- Authority
- JP
- Japan
- Prior art keywords
- glutaminase
- cells
- pseudomonas
- tumor
- dna molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010073324 Glutaminase Proteins 0.000 title claims abstract description 184
- 102000009127 Glutaminase Human genes 0.000 title claims abstract description 163
- 230000000840 anti-viral effect Effects 0.000 title description 4
- 238000011319 anticancer therapy Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 77
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 56
- 241000920685 Pseudomonas sp. 7A Species 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 23
- 102000053602 DNA Human genes 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 241000589516 Pseudomonas Species 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 108020004705 Codon Proteins 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 7
- 108010033586 polyethylene glycol-glutaminase-asparaginase Proteins 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 230000005030 transcription termination Effects 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 101710192545 Glutaminase A Proteins 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 241000720950 Gluta Species 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 9
- 239000002158 endotoxin Substances 0.000 abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 abstract description 4
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 210000000481 breast Anatomy 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 35
- 108090000790 Enzymes Proteins 0.000 description 35
- 229940088598 enzyme Drugs 0.000 description 35
- 230000000694 effects Effects 0.000 description 32
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 239000012634 fragment Substances 0.000 description 20
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 108010024976 Asparaginase Proteins 0.000 description 7
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 7
- 229930195715 D-glutamine Natural products 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000015790 Asparaginase Human genes 0.000 description 6
- 229960003272 asparaginase Drugs 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 101150109249 lacI gene Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000932047 Achromobacter sp. Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000009088 enzymatic function Effects 0.000 description 3
- 108010042430 galactose receptor Proteins 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 102220201851 rs143406017 Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 101100242814 Caenorhabditis elegans parg-1 gene Proteins 0.000 description 2
- 101100350997 Caenorhabditis elegans parg-2 gene Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101150016593 PGA gene Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003127 anti-melanomic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 150000001508 asparagines Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002308 glutamine derivatives Chemical class 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101100499417 Chlamydia pneumoniae dnaA1 gene Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 229930182846 D-asparagine Natural products 0.000 description 1
- 108030006828 D-glutaminases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000879141 Fusarium tricinctum Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101001116388 Homo sapiens Melatonin-related receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 101100353036 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pme-1 gene Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 101150020338 dnaA gene Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940127195 glutamine antimetabolite Drugs 0.000 description 1
- 108010016102 glutamine transport proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01038—Glutamin-(asparagin-)ase (3.5.1.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.HIV感染細胞への上述の細胞中でHIVの複製を阻害するのに十分な量 の治療上適切なグルタミナーゼを投与することよりなる、HIV感染細胞中のH IVの複製を阻害する方法。 2.グルタミナーゼがシュードモナスグルタミナーゼである請求項1に記載の 方法。 3.グルタミナーゼがシュードモナス7Aグルタミナーゼである請求項1に記 載の方法。 4.治療上適切なグルタミナーゼおよび腫瘍関連抗原を発現している腫瘍細胞 に対する腫瘍関連抗原と免疫反応する抗体が結合した複合体を、該細胞のDNA 合成を阻害するのに十分な量投与することよりなる、癌細胞の増殖を阻害する方 法。 5.グルタミナーゼがシュードモナスグルタミナーゼである請求項4に記載の 方法。 6.グルタミナーゼがシュードモナス7Aグルタミナーゼである請求項5に記 載の方法。 7.癌細胞がメラノーマ細胞である請求項4に記載の方法。 8.シュードモナス7Aグルタミナーゼ−アスパラギナーゼ遺伝子を含む大腸 菌細胞。 9.寄託番号69117としてATCCに寄託されている請求項8に記載の細 胞。 10.上記の遺伝子を発現可能な請求項8に記載の細胞。 11.遺伝子がSEQ ID NO:1に示したヌクレオチド配列をもつ請求 項8に記載の細胞。 12.治療上適切なグルタミナーゼをコードするヌクレオチド配列を含む単離 および精製されたDNA分子。 13.グルタミナーゼがシュードモナスグルタミナーゼである請求項12に記 載のDNA分子。 14.グルタミナーゼがシュードモナス7Aグルタミナーゼである請求項12 に記載のDNA分子。 15.SEQ ID NO:1に示したヌクレオチド配列を含む請求項12に 記載のDNA分子。 16.組換え細胞中でグルタミナーゼを発現する事が可能である請求項12に 記載のDNA分子。 17.グルタミナーゼがSEQ ID NO:2に示した配列をもつ請求項1 2に記載のDNA分子。 18.グルタミナーゼの発現が誘導可能なプロモーターによって制御されてい る請求項12に記載のDNA分子。 19.グルタミナーゼの発現がレプレッサーによって制御されている請求項1 2に記載のDNA分子。 20.プロモーターがtacである請求項18に記載のDNA分子。 21.グルタミナーゼ配列の3’および5’に転写終結点(ターミネーター) を含む請求項16に記載のDNA分子。 22.成熟グルタミナーゼの最初のリジンコドンの5’にメチオニンコドンを 持つ請求項14に記載のDNA分子。 23.シュードモナスエンドトキシンを含まない治療上適切なグルタミナーゼ の無細胞調製物。 24.グルタミナーゼがシュードモナスグルタミナーゼである請求項23に記 載の調製物。 25.グルタミナーゼがシュードモナス7Aグルタミナーゼである請求項23 に記載の調製物。 26.他のシュードモナスのタンパク質を含まない、請求項22に記載の調製 物。 27.治療上適切なグルタミナーゼをコードするDNA配列を含む組換え微生 物を培養し;そして 上記微生物によって生産されたタンパク質を回収する; 過程により製造される請求項22に記載の調製物。 28.グルタミナーゼがSEQ ID NO:2に示された配列をもつ請求項 23に記載の調製物。 29.成熟グルタミナーゼの最初のリジンの前にメチオニンを持つ請求項25 に記載の調製物。 30.SEQ ID NO:1のヌクレオチド配列を含むプラスミドを投与す ること、該配列は組織特異的なプロモーターの転写制御下にあること、そして該 プラスミドは組織特異的なリガンドに共有結合したポリ−L−リジンで被われて いること、よりなる、身体中の形質転換された細胞を処理する方法。 31.形質転換された細胞が肝臓細胞である請求項30に記載の方法。 32.治療上適切なグルタミナーゼおよび腫瘍関連抗体に特異的な抗体を含む 複合体を含む、治療組成物。 33.グルタミナーゼおよび抗体が共有結合している請求項32に記載の組成 物。 34.グルタミナーゼおよび抗体がキメラタンパク質の部分である請求項32 に記載の組成物。 35.グルタミナーゼがシュードモナスグルタミナーゼである請求項32に記 載の組成物。 36.グルタミナーゼがシュードモナス7Aグルタミナーゼである請求項35 に記載の組成物。 37.抗体がメラノーマ関連抗原に特異的な抗体である請求項32に記載の組 成物。 38.抗体とグルタミナーゼが共有結合している請求項4に記載の方法。 39.抗体およびグルタミナーゼがキメラタンパク質の部分である請求項4に 記載の方法。 40.SEQ ID NO:1のヌクレオチド配列を含むプラスミドを投与す ること、該配列は組織特異的プロモーターの転写制御下にあること、そして該プ ラスミドは織特異的リガンドを含む正に荷電したリポソームによって被われてい ること、よりなる、身体中の形質転換した細胞の処理方法。 41.形質転換した細胞が肝臓細胞である請求項30に記載の方法。 42.腫瘍を持つ患者からの腫瘍に浸潤するリンパ細胞を得ること; ヒト細胞中でシュードモナス7Aグルタミナーゼの発現を起こすベクターによ り上記の腫瘍に浸潤するリンパ細胞を形質転換すること;および 患者の腫瘍にシュードモナス7Aグルタミナーゼを供給するために上記の形質 転換した腫瘍に浸潤するリンパ細胞を患者へ投与すること; の段階を含む、腫瘍患者の治療方法。 43.腫瘍患者から腫瘍に浸潤するリンパ細胞を得ること; 上記の腫瘍に浸潤するリンパ細胞と、ヒト細胞中でシュードモナス7Aグルタ ミナーゼを発現するSEQ ID NO:1のヌクレオチド配列を含むベクター を組み合わせること;および 患者の腫瘍にシュードモナス7Aグルタミナーゼを供給するために上記のリン パ細胞とベクターの複合体を腫瘍患者へ投与すること; の段階を含む腫瘍患者の治療方法。 44.上述のベクターがポリ−L−リジンでコートされている請求項43に記 載の方法。 45.上述のポリ−L−リジンが組織特異的リガンドと共有結合している請求 項44に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1992/010421 WO1994013817A1 (en) | 1992-12-04 | 1992-12-04 | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003420050A Division JP3727635B2 (ja) | 2003-12-17 | 2003-12-17 | 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502082A true JPH09502082A (ja) | 1997-03-04 |
JP4007516B2 JP4007516B2 (ja) | 2007-11-14 |
Family
ID=38068995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51406694A Expired - Fee Related JP4007516B2 (ja) | 1992-12-04 | 1992-12-04 | 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6312939B1 (ja) |
EP (1) | EP0692029B1 (ja) |
JP (1) | JP4007516B2 (ja) |
AT (1) | ATE361984T1 (ja) |
AU (1) | AU3235893A (ja) |
CA (1) | CA2149922C (ja) |
DE (1) | DE69233695T2 (ja) |
ES (1) | ES2287926T3 (ja) |
WO (1) | WO1994013817A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527232A (ja) * | 2003-06-11 | 2006-11-30 | メディカル エンザイムズ アクチエンゲゼルシャフト | グルタミナーゼ及び抗新生物性のアントラサイクリン類又は白金化合物を含有する癌治療のための薬剤学的な組合せ製剤 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6342345B1 (en) * | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
JP3904185B2 (ja) * | 2001-06-21 | 2007-04-11 | キッコーマン株式会社 | グルタミナーゼ、グルタミナーゼ遺伝子、新規な組み換え体dna及びグルタミナーゼの製造法 |
TWI319007B (en) * | 2002-11-06 | 2010-01-01 | Novozymes As | Subtilase variants |
WO2007001395A2 (en) * | 2004-10-04 | 2007-01-04 | University Of South Carolina | Prevention and treatment of influenza with glutamine antagonist agents |
US8465736B2 (en) * | 2006-05-10 | 2013-06-18 | New Medical Enzymes Ag | Glutadon |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US8784846B2 (en) * | 2007-07-30 | 2014-07-22 | Loma Linda University Medical Center | Systems and methods for particle radiation enhanced delivery of therapy |
US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
US20110201022A1 (en) | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
HUE039516T2 (hu) | 2010-02-04 | 2019-01-28 | Biomarin Pharm Inc | Eljárás prokarióta fenilalanin-liáz variánsok tisztítására |
WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
WO2014043633A1 (en) | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
CN105372432B (zh) * | 2014-08-22 | 2017-10-03 | 南京大学(苏州)高新技术研究院 | Gls1酶在制备肝癌诊断试剂盒中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1168150A (en) | 1981-12-18 | 1984-05-29 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
JPS58209980A (ja) * | 1982-04-27 | 1983-12-07 | Kyowa Hakko Kogyo Co Ltd | 酵素の精製法 |
US5232840A (en) * | 1986-03-27 | 1993-08-03 | Monsanto Company | Enhanced protein production in bacteria by employing a novel ribosome binding site |
JPH01300889A (ja) * | 1988-05-30 | 1989-12-05 | Ajinomoto Co Inc | 形質転換体及びこれを用いるMTGaseの製造法 |
-
1992
- 1992-12-04 EP EP93900818A patent/EP0692029B1/en not_active Expired - Lifetime
- 1992-12-04 AU AU32358/93A patent/AU3235893A/en not_active Abandoned
- 1992-12-04 AT AT93900818T patent/ATE361984T1/de active
- 1992-12-04 DE DE69233695T patent/DE69233695T2/de not_active Expired - Lifetime
- 1992-12-04 WO PCT/US1992/010421 patent/WO1994013817A1/en active IP Right Grant
- 1992-12-04 CA CA002149922A patent/CA2149922C/en not_active Expired - Fee Related
- 1992-12-04 US US08/050,482 patent/US6312939B1/en not_active Expired - Lifetime
- 1992-12-04 ES ES93900818T patent/ES2287926T3/es not_active Expired - Lifetime
- 1992-12-04 JP JP51406694A patent/JP4007516B2/ja not_active Expired - Fee Related
-
2001
- 2001-04-27 US US09/842,628 patent/US7052689B2/en not_active Expired - Fee Related
-
2006
- 2006-05-03 US US11/416,133 patent/US20060240414A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527232A (ja) * | 2003-06-11 | 2006-11-30 | メディカル エンザイムズ アクチエンゲゼルシャフト | グルタミナーゼ及び抗新生物性のアントラサイクリン類又は白金化合物を含有する癌治療のための薬剤学的な組合せ製剤 |
Also Published As
Publication number | Publication date |
---|---|
WO1994013817A1 (en) | 1994-06-23 |
EP0692029A1 (en) | 1996-01-17 |
US20020064862A1 (en) | 2002-05-30 |
ATE361984T1 (de) | 2007-06-15 |
JP4007516B2 (ja) | 2007-11-14 |
ES2287926T3 (es) | 2007-12-16 |
CA2149922A1 (en) | 1994-06-23 |
EP0692029B1 (en) | 2007-05-09 |
US7052689B2 (en) | 2006-05-30 |
US6312939B1 (en) | 2001-11-06 |
DE69233695T2 (de) | 2008-01-24 |
US20060240414A1 (en) | 2006-10-26 |
DE69233695D1 (de) | 2007-06-21 |
CA2149922C (en) | 2007-05-15 |
AU3235893A (en) | 1994-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060240414A1 (en) | Genetically engineered glutaminase and its use in antiviral and anticancer therapy | |
Debinski et al. | Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. | |
US6022950A (en) | Hybrid molecules having translocation region and cell-binding region | |
AU657087B2 (en) | Hybrid molecules having translocation region and cell-binding region | |
EP0583794B1 (en) | Recombinant pseudomonas exotoxin: construction of an active immunotoxin with low side effects | |
EP0896625B1 (en) | Recombinant ribonuclease proteins | |
AU752370B2 (en) | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence | |
JP2610740B2 (ja) | 標的特異的細胞障害性組み換えシュードモナスエキソトキシン | |
JP3727635B2 (ja) | 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用 | |
EP1854876A2 (en) | Genetically engineered glutaminase and its use in antiviral and anticancer therapy | |
EP1085908B1 (en) | Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein | |
JP2676336B2 (ja) | ヒトb細胞分化因子の遺伝子 | |
JP3532193B2 (ja) | 細胞の増殖または走化性の調節に使用するチミジンホスホリラーゼ | |
CN113817071B (zh) | 一种egfr靶向的trail融合蛋白及其制备方法和用途 | |
US20030027311A1 (en) | Recombinant anti-tumor RNAse | |
CA2245804C (en) | Recombinant ribonuclease proteins | |
JP2002512774A (ja) | 組換えオンコナーゼと、その化学的接合体および融合タンパク質 | |
EP1068332B1 (en) | Recombinant anti-tumor rnase | |
EP1219706A2 (en) | Production processes for recombinant wolinella succinogenes asparaginase | |
Zhang et al. | Fusion protein of interleukin 4 and diphtherial toxin with high cytotoxicity to cancer cells | |
JP2832358B2 (ja) | モノクローナル抗体の増収法 | |
JPH06336497A (ja) | B細胞分化因子及びその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20031211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20031217 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20031217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040116 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040715 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070704 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070824 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100907 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100907 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110907 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |